Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05309460
Other study ID # NebraskaMethodistHS
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 20, 2022
Est. completion date December 1, 2024

Study information

Verified date April 2024
Source Nebraska Methodist Health System
Contact Todd Lovgren, MD
Phone 4028151970
Email todd.lovgren@nmhs.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.


Description:

Enrollment: Patients will be identified daily using an EMR screening tool. Those that meet inclusion criteria will then be approached by the investigators or research RN for enrollment. Patients consenting to be involved in the study will then be randomly assigned to the nifedipine or labetalol arms of the study. Block randomization will be performed in blocks of 50 with goal of 600 total patients (300 in each arm). Treatment Protocols Nifedipine Study Arm: Patients randomized to Nifedipine will be started on Nifedipine XR 30mg BID. Escalation in therapy to be determined by primary provider. Maximum dose of Nifedipine is 120mg daily. All patients will be monitored for signs and symptoms of hypotension or medication side effect- severe HA, orthostasis, syncope. Patients with further hypertension will then be started on Labetalol as a second agent at 200mg TID and escalated as needed with the goal of being normotensive for at least 12 hours before discharge. Patients will not be kept hospitalized for purposes of the study. Labetalol Study Arm: Patients randomized to Labetalol will be started on 200mg TID. Escalation in therapy to be determined by primary provider. Maximum dose is 2400mg in a day. All patients will be monitored for signs and symptoms of hypotension or medication side effect- orthostasis, syncope, bradycardia. Patient's that reach 800mg TID or cannot escalate therapy due to bradycardia will then be started on Nifedipine 30mg BID and escalated as needed with the goal of normotension for at least 12 hours before discharge. Patients will not be kept hospitalized for purposes of the study. All Patients: Outpatient follow up to be dictated by the discharging provider. Patients will be called at 6 months to determine if they were readmitted and their MRN will be used to query the EMR for readmission or ER evaluation. Power Calculation Anticipated incidence in Nifedipine arm is 1%. Pilot study indicated a readmission risk of 0.2% in patients discharge normotensive on nifedipine. We anticipate this will be higher as some patients will likely be discharged with HTN. Anticipated incidence in the Labetalol arm is 7%. This number was based on a 5.8% risk of readmission in the normotensive group and 12.6% in the hypertensive group. As with the nifedipine arm, we anticipate there will be some patients discharged hypertensive increasing this risk above that of patients discharged normotensive. With alpha set at 0.05 and power of 80%, we anticipate we will need at least 332 total patients, 166 in each arm. The original pilot data included patients with both physician identified hypertensive disease as well as those patients only identified by the EMR screening tool. Those patients identified by the screening tool had an increased risk of readmission compared to the overall population based risk of readmission (3.6% vs 1%). Their risk is lower than those patients identified by their provider 5.2%. Our plan is to enroll 600 patients, 300 in each arm as some patients will require multiple medications and due to the dilution of including a lower risk group we feel the initial power calculation does not take these factors into account. All data will be analyzed by intention to treat and crossover between groups for side effects or primary physician change in management will be reported/monitored. Data Safety Monitoring Data will be reviewed q 6 months for statistical significance once at least 100 patients have been enrolled in each arm. If the effect is statistically significant to a p of 0.05 the study will be terminated for safety reasons. The DSMB will also monitor patient crossover and medication side effects as part of their evaluation. Data safety monitoring board will be comprised of 2 maternal fetal medicine physicians, 1 general obstetrician and the study research RN. Data will be analyzed as each block in the randomization is completed.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date December 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 19 Years and older
Eligibility Inclusion Criteria: Any patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure =140mmHg or diastolic blood pressure =90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension. Exclusion Criteria: History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema - Contraindication to either Nifedipine or Labetalol - HR <60 or >110 - Native language other than English or Spanish

Study Design


Intervention

Drug:
Labetalol Oral Tablet
See Labetalol arm.
NIFEdipine ER
See Nifedipine arm.

Locations

Country Name City State
United States Nebraska Methodist Women's Hospital Omaha Nebraska

Sponsors (1)

Lead Sponsor Collaborator
Nebraska Methodist Health System

Country where clinical trial is conducted

United States, 

References & Publications (2)

Lovgren T, Connealy B, Yao R, D Dahlke J. Postpartum medical management of hypertension and risk of readmission for hypertensive complications. J Hypertens. 2023 Feb 1;41(2):351-355. doi: 10.1097/HJH.0000000000003340. Epub 2022 Dec 13. — View Citation

Lovgren T, Connealy B, Yao R, Dahlke JD. Postpartum management of hypertension and effect on readmission rates. Am J Obstet Gynecol MFM. 2022 Jan;4(1):100517. doi: 10.1016/j.ajogmf.2021.100517. Epub 2021 Oct 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Readmission Patients will be monitored following delivery for readmission to the hospital. To improve patient capture, all patients will be called at 6 months to identify complications or if hospital admission occured in the 6 months following delivery 6 months
Secondary Medication failure Need for additional antihypertensive medication Any time during the 6 months following delivery
Secondary Medication change or discontinuation Need to change medication or discontinue medication due to side effects or complications of medication. Any time during the 6 months following delivery
See also
  Status Clinical Trial Phase
Completed NCT00974714 - L-arginine Effects on Chronic Hypertension in Pregnancy Phase 3
Terminated NCT03595982 - Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily? Phase 4
Completed NCT04486170 - Assessment of Postpartum Education to Improve Compliance N/A
Completed NCT03506724 - Response to Anti-hypertensives in Pregnant and Postpartum Patients Phase 4
Completed NCT03613714 - Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy N/A
Recruiting NCT04604535 - The BEET-BP Trial - Investigating the Effect of Dietary Nitrates on Hypertension in Pregnancy N/A
Completed NCT00412230 - Insulin Resistance and Hypertensive Disorders in Pregnancy N/A
Active, not recruiting NCT05049616 - Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension Phase 4
Completed NCT04119232 - Randomized Clinical Trial to Increase Physical Activity After a a Hypertensive Pregnancy N/A
Completed NCT04633551 - Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes N/A
Completed NCT05859282 - Development and Validation of a Short Tool to Assess the Awareness of Pregnancy-induced Hypertension
Active, not recruiting NCT05543265 - Bridging the Gap From Postpartum to Primary Care N/A
Completed NCT00571766 - Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy Phase 3
Recruiting NCT05473767 - Expanding the Family Check-Up in Early Childhood to Promote Cardiovascular Health of Mothers and Young Children N/A
Recruiting NCT05683093 - Cardiovascular Longitudinal ALSPAC Research Investigations Following Hypertensive Pregnancy in Young Adulthood
Completed NCT06403722 - Perinatal Outcomes in Patients With Elevated sFlt-1/PlGF Ratio
Recruiting NCT05852054 - Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP) Phase 3
Recruiting NCT05137808 - Understanding Blood Pressure Changes After Birth
Completed NCT03961360 - Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida Phase 2/Phase 3
Active, not recruiting NCT03648645 - Hypertensive Pregnant Women Monitored by Teletransmitted Self-measurements of Blood Pressure N/A